Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats

British Journal of Nutrition

Volumn 96, Issue 4, 2006, Pages 660-666

  Al Amin, Zainab M ^a   Thomson, Martha ^a   Al Qattan, Khaled K ^a   Ali, Muslim ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Anti diabetic properties; Diabetes; Ginger; Hypoglycaemic properties; Hypolipidaemic properties; Proteinuria

Indexed keywords

CHOLESTEROL; GINGER EXTRACT; GLUCOSE; STREPTOZOCIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; FLUID INTAKE; GINGER; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPOCHOLESTEROLEMIA; HYPOGLYCEMIA; HYPOLIPEMIA; MALE; NONHUMAN; PROTEIN URINE LEVEL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; URINE VOLUME; WEIGHT REDUCTION; ANIMAL; BLOOD; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; METHODOLOGY; PHYTOTHERAPY; SPRAGUE DAWLEY RAT;

RATTUS; ZINGIBER OFFICINALE;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; GINGER; HYPOGLYCEMIC AGENTS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 33947274715     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1079/BJN20061849     Document Type: Article

References (48)

1. Abdel-Aziz H, Nahrstedt A, Peterelt F, Windeck T, Ploch M & Verspohl EJ (2005) 5-HT3 receptor blocking activity of arhyalkanes isolated from the rhizome of Zingiber officinale. Planta Med 71, 609-616.
2. Akhani SP, Vishwakarma SL & Goyal RK (2004) Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats. J Pharm Pharmacol 56, 101-105.
3. Alnaqeeb MA, Thomson M, Al-Qattan KK, Kamel F, Mustafa T & Ali M (2003) Biochemical and histopathological toxicity of ginger (Zingiber officinale) in rats. Kuwait J Sci Eng 30, 35-48.
4. Axler DA (1982) Stability of the diabetogenic activity of streptozotocin. IRCS Med Sci 10, 157-165.
5. Bailey CJ & Day C (1989) Traditional plant medicines as treatments for diabetes. Diabetes Care 12, 553-564.
6. Bailey CJ & Flatt PR (1990) New Antidiabetic Drugs. London: Smith-Gordon.
7. Bhandari U, Kanojia R & Pillai KK (2005) Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol 97, 227-230.
8. Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt H-H, Christensen K, Jensen ON & Barslev J (2000) A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 8, 9-12.
9. Bordia A, Verma SK & Srivastava KC (1997) Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Tringonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostagl Leukotr Essen Fatty Acids 56, 379-384.
10. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
11. Cady RK, Schreiber CP, Beach ME & Hart CC (2005) Gelstat Migraine® (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. Med Sci Monit 11, 165-169.
12. Chevallier A (1996) The Encyclopedia of Medicinal Plants. London: Dorling Kindersley Ltd..
13. Chua DY & Bakris GL (2004) Diabetes and chronic kidney disease: Tragedy and challenge. Blood Purif 22, 130-135.
14. Clark CM & Lee DA (1995) Drug therapy: Prevention and treatment of complications of diabetes mellitus. N Engl J Med 332, 1210-1217.
15. Ernst E & Pittler MH (2000) Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Brit J Anaes 84, 367-371.
16. Fuhrman B, Rosenblat M, Hayek T, Coleman R & Aviram M (2000) Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. J Nutr 130, 1124-1131.
17. Govindarajan VS (1982a) Ginger - chemistry, technology, and quality evaluation: Part 1. Crit Rev Food Sci Nutr 17, 1-96.
18. Govindarajan VS (1982b) Ginger - chemistry, technology, and quality evaluation: Part 2. Crit Rev Food Sci Nutr 17, 189-258.
19. Grant KI (2000) Ginger. Am J Heath Syst Pharm 57, 945-947.
20. Gray AM & Flatt PR (1997) Nature's own pharmacy: The diabetes perspective. Proc Nutr Soc 56, 507-517.
21. Gray AM & Flatt PR (1999) Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant Coriandrum sativum (coriander). Br J Nutr 81, 203-209.
22. Hill JO & Peters JC (2002) Biomarkers and functional foods for obesity and diabetes. Br J Nutr 88, Suppl., S213-S218.
23. Huang QR, Iwanmoto M, Aoki S, Tanaka N, Tajima K, Yamahara J, Takaishi Y, Yoshida M, Tomimatsu T & Tamai Y (1991) Anti-5-hydroxytryptamine3 effect of galanolactone, diterpenoid isolated from ginger. Chem Pharm Bull (Tokyo) 39, 397-399.
24. Kar A, Choudhary BK & Bandyopadhyay NG (2003) Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxa diabetic rats. J Ethnopharmacol 84, 105-108.
25. Kim E-C, Min J-K, Kim T-Y, Lee S-J, Yang H-O, Han S, Kim Y-M & Kwon Y-G (2005) [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Comm 335, 300-308.
26. Kiuchi F, Iwakami S, Shibuya M, Hanaoka F & Sankawa U (1992) Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem Pharm Bull (Tokyo) 40, 387-391.
27. Koda-Kimble MA & Carlisle BA (1995) Diabetes mellitus. In Applied Therapeutics: The Clinical Use of Drugs, 6th ed. pp. 48-1-48-58 [LY Young, MA Koda-Kimble, WA Kradjan and BJ Guglielmo, editors]. Vancouver, BC, Canada: Applied Therapeutics.
28. McKenna DJ, Jones K, Hughes K & Humphrey S (2002) Ginger. In Botanical Medicines, the Desk Reference for Major Herbal Supplements, 2nd ed. pp, 411-444. New York: The Haworth Herbal Press.
29. Mascolo N, Jain R, Jain SC & Capasso F (1989) Ethnopharmacologic investigation of ginger (Zingiber officinale). J Ethnopharmacol 27, 129-140.
30. Mustafa T & Srivastava KC (1990) Ginger (Zingiber officinale) in migraine headache. J Ethnopharmacol 29, 267-273.
31. Mustafa T, Srivastava KC & Jensen KB (1994) Drug development report (9): Pharmacology of ginger, Zingiber officinale. J Drug Dev 6, 25-39.
32. National Research Council (1996) Veterinary medical care. In Guide for the Care and Use of Laboratory Animals, pp. 56-70. Washington, DC: National Academy Press.
33. Nathan DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328, 1676-1685.
34. Penna SC, Medeiros MV, Aimbire FS, Faria-Neto HC, Sertie JA & Lopes-Martins RA (2003) Anti-inflammatory effect of the hydralcoholic extract of Zingiber officinale rhizomes on rat paw and skin edema. Phytomed 10, 381-385.
35. Portnoi G, Chng LA, Karimi-Tabesh L, Koren G, Tan MP & Einarson A (2003) Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol 189, 1374-1377.
36. Sharma M & Shukla S (1977) Hypoglycaemic effect of ginger. J Res Ind Yoga Homeop 12, 127-130.
37. Singhal PC & Joshi LD (1983) Glycaemic and cholesterolemic role of ginger and till. J Sci Res Plants Med 4, 32-34.
38. Srinvasan K (2005) Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. Int J Food Sci Nutr 56, 399-414.
39. Srivastava KC & Mustafa T (1989) Ginger (Zingiber officinale) and rheumatic disorders. Med Hyp 29, 25-28.
40. Srivastava KC & Mustafa T (1992) Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hyp 39, 342-348.
41. Swanston-Flatt SK, Flatt PR, Day C & Bailey CJ (1991) Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc 50, 641-651.
42. Thomson M, Al-Qattan KK, Al-Sawan SM, Alnaqeeb MA, Khan I & Ali M (2002) The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostagl Leukotr Essen Fatty Acids 67, 475-478.
43. Ursell A (2000) The Complete Guide to Healing Foods, pp. 112-114. London: Dorling Kindersley Ltd.
44. Viberti GC, Hill RD, Jarett RJ, Argyropolous A, Mahmud U & Kern H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet i, 1430.
45. Weidner M & Sigwart K (2000) The safety of a ginger extract in the rat. J Ethnopharmacol 73, 513-520.
46. White DA & Baxter M (1994) Diabetes mellitus. In Hormones and Metabolic Control, 2nd ed. pp. 79-92 [DA White and M Baxter, editors]. London: Arnold.
47. World Health Organization (1980) World Health Organization Expert Committee on Diabetes Mellitus, Second Report. Technical Report Series no. 646, pp. 66. Geneva: WHO.
48. Yamada J, Sugimoto Y & Inoue K (1999) Selective serotonin reuptake inhibitors fluoxetine and fluvosamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 382, 211-215.